(f) if so, what are the names of the intermediates imported by each producer, quantity imported by each producer of each intermediate during the last three years, year-wise, along with source of import;

(g) whether it is a fact that some of these producers are overinvoicing the import of intermediates; and

(h) who is the agent of the importing source in India ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) and (b) Details to the extent available are given below: —

	Fioduction (Kgs.)		
	1986-87	1987-88	1988-89
Merinci	236-32	134	258
Cadila	84-86	94	85

(c) and (d) BICP studied the cost structure of this drug and sent its report in March, 1989. Data of Merind Ltd. and M/s. Cadila Labs. Pvt. Ltd. was studied by the BICP. The price of Dexa-methasone pure was fixed at Rs. 92 per gm. and that of Dexamethasone 21 phosphate at Rs. 97 per gm. w. e. f. 10th Nov., 1989.

(e) and (f) Dexamethasone is being produced in the country from imported alfa teriene by M/s. Merind and Cadila Labs. Details regarding quantity imported, their CIF values and source of imports are not monitored by this Ministry.

(g) Nothing to this effect has come to the notice of the Govt, recently.

(h) Government does not monitor this type of information.

गोविन्द बल्लभ पंत अस्पताल नई दिल्ली में डाक्टर की नियुक्ति

2948. **श्रीमती सत्या बहिन** : क्या **स्वास्थ्य एवं परिवार कल्याण मंत्रालय** यह बताने की कृपा करेंगे कि :

(क) क्या यह सच है कि केन्द्रीय गृह मंत्री की पुत्री को गोविन्द बल्लभ पंत अस्पताल, नई दिल्ली में नियुक्त किया गया है;

(ख) यदि हां, तो उन्हें किस पद पर नियुक्त किया गया है और क्या उक्त पद के लिए विज्ञापन दिया गया था ;

(ग) यदि हां, तो विज्ञापन के उत्तर में कितने आवेदनपत्र प्राप्त हुए थे ;

(घ) क्या इस मामले में भर्ती के नियमों में ढील दी गई थी ; और

(ङ) यदि हां, तो दिल्ली के अस्पतालों में गत दो वर्षों के दौरान भर्ती नियमों में ढील देकर ऐसी कितनी अन्य नियुक्तियां की गई हैं ?

स्वास्थ्य एवं परिवार कल्याण मंत्रालय में राज्य मंत्री (श्री रशीद मसूद) : (क) जी, नहीं ।

(ख) से (ङ) ये प्रश्न नहीं उठते ।

Consideration of drug issues by Standing Committee

2949. SHRI BEKAL UTSAHI: SHRI RAINIRANJAN SAHU:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Starred

Question 149 given in the Rajya Sabha on 20th August, 1990 and state:

(a) what are the details of various aspects concerning Drugs Prices Control Order being considered by Standing Committee;

(b) on which aspects the Standing Committee has sent recommendations to Government;

(c) what are the details of issues on which Government have taken the decision;

(d) what is the position of implementation of each decision;

(e) what are the names of drugs on which the Standing Committee has sent recommendations and on how many drugs decision has been sent;

(f) whether it is a fact that the Standing Committee is considering the issues of MAPE, Trade Commission, Profitability, Wholesale, Price Index, etc.;

(g) whether his Ministry has conducted any study on these aspects before these issues could be considered by the Standing Committee; and

(h) if so, what are the details thereof and if not, on what basis recommendations would be made ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) There are a number of issues like wrong exclusion of several bulk drugs from price control lists, exemption from price control to small scale units in respect of Category II formulations, inclusion of more drugs under price control etc. on which representations have been received by the Government. All these will be considered by the Standing Committee.

(b) to (e) The details of Govern ment's decision taken so far on the recommendations made by the Standing Committee have been given in reply to Rajya Sabha Unstarred Question No. 899 dated 13-8-1990. These are at different stages of implementation. It is not in public interest to disclose the other recommendations of the Standing Committee at this stage.

(f) to (h) The Standing Committee will examine these issues independently for the review of the 1986 policy for which adequate data is available.

Price control on Hydroprogesterone and Glybenclamide

2950. DR. RATNAKARPANDEY:
SHRI RAJNI RANJAN SA-HU:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1346 given in the Rajya Sabha on 20th August, 1990 and state:

(a) what was the sales turn over of Hydroprogesterone and Glybenclamide during the last three years, yearwise;

(b) what are the names of producers of both these drugs;

(c) since when the recommendations of Standing Committee in respect of these drugs are pending with the Government for decision and by when decision would be taken;

(d) what are the names of other drugs for which decision on the recommendations of Standing Committee in respect of exclusion or inclusion of drugs is pending with Government for decision and by when decision on each would be taken;

(e) whether it is a fact that unnecessary loading of prices is being done by BICP on determination of fair prices of drugs; and